Team Medical Affairs News Contact

Team Medical Affairs News Contact

Back

In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii

January 1, 2018

A subsidiary of Innoviva, Inc.

Innoviva is a diversified holding company with a portfolio of royalties and other healthcare assets. Learn more at inva.com

Privacy Policy | Terms of Use

Team Medical Affairs News Contact

A subsidiary of Innoviva, Inc.

Innoviva is a diversified holding company with a portfolio of royalties and other healthcare assets. Learn more at inva.com

Privacy Policy | Terms of Use

© 2023 INNOVIVA SPECIALTY THERAPEUTICS | ALL RIGHTS RESERVED